Drug Trial Radar · NCT07308184
Bridge Study to Evaluate the Efficacy and Safety of IN-B00009 Injection in Patients With T2DM Inadequately Controlled by Diet and Exercise Alone
Last checked: Nov 20, 2026Latest source record: Dec 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
110
Planned (sponsor's estimate)
Start
Dec 2025
Primary completion
Aug 2027
Study completion Sep 2027
Sponsor
- Lead sponsor
- HK inno.N CorporationIndustry
- Sponsor type
- Industry
- First posted
- Dec 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 3 Bridge study is designed to evaluate the efficacy and safety of IN-B00009 Injection in Patients with T2DM Inadequately Controlled by Diet and Exercise Alone
Conditions
- Diabetes (DM)
- Diabetes Mellitus Type 2
Interventions
IN-B00009Drug
Test drug
PlaceboDrug
Placebo drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- A change in HbA1c from baseline at Week 24Time frame: Baseline, 24 Weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.